|
Editor's Note:
The CFRI Research
Advisory Committee voted to fund only one cycle of funding in future
years. Research proposals requesting funding in 2001 must be submitted
to the CFRI office no later than July 2nd.
The final vote by the Board of Directors and the General Membership on
the RAC's recommendation for funding will occur at the end of October,
2001. The total funds awarded in 2000 amounted to $173,787.
Spring Cycle
-
Jeff Wine,
Ph.D.,
Stanford
University, Stanford,
California,
Principal Investigator and Rabin Tirouvanziam, Ph.D., Research
Scientist.
CFTR, Glutathione (GSH) and Neutrophil Function.
This study is
testing whether cells lacking the CF chloride channel release less
glutathione (GSH) into their environment such that microbe-killing
mechanism of the neutrophils is impaired. Dr. Tirouvanziam's goal is to
provide a model for the small airways which provides understanding on
the use of CFTR to transport GSH and
support neutrophils during the microbe-killing process.
Amount funded:
$44,287
-
John LiPuma,
M.D., University of Michigan Medical Center, Ann Arbor, MI, Principal
Investigator.
Prevalence of Sputum Culture Negative Burkholderia
Cepacia Colonization in
Northern California CF Centers.
This is a request
for an additional six months of funding to study gram negative cultures
in Northern California CF centers.
Amount funded:
$23,000
Fall
Cycle
-
Jonathan Widdicome, Ph.D., Children's Hospital Oakland Research Institute,
Oakland,
CA.
Program Director of the CFRI Bay
Area Fellowship/Post-Doctoral Training Program in Cystic Fibrosis.
The CFRI Fellowship
Training Program continues to expand. Ultimately, annual funding will
reach $175,000 per year for a five-year commitment.
Funds allocated in 2000:
$32,500
-
Tomas
Ganz, Ph.D., M.D., Professor of Medicine and Pathology, University of
California, Los Angeles, School of Medicine, Los Angeles, CA.
Antimicrobial Deficiency of CF Airways
Secretions.
This
research project has proposed to identify protein determinants of CF
airways colonization by identifying and comparing microbicidal
components of non-CF and CF nasal fluids. The studies will examine
differences in the number and activity of natural antibiotics, called
antimicrobial peptides or "AMPs". Also studies will compare the protein
patterns of nasal fluid from CF patients to both non-CF donors and
Staph-carriers. These two lines of investigation will determine
components specifically defective in CF airways. Defective
antimicrobials could ultimately be therapeutically replaced to restore
the natural antibiotic activity of CF airways secretions.
Amount funded:
$54,000
-
Martin Kharazzi, Ph.D., Research Scientist, Genetic Disease Branch, Department
of
Health Services in Berkeley, California for the state of California.
Cystic Fibrosis Mutation Frequencies in
Hispanic Adults.
This study seeks to
analyze and determine the most frequent CF mutations for Hispanics and
other minorities in California in an effort to support a newborn
screening process adequate for the cross-cultural population of the
state. Currently many mutations common to the Hispanic population are
unknown.
Amount funded:
$20,000
|